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Abstract
Background: There have been dramatic changes in the approach to screening for aneuploidy over
the last 20 years. However, the approach to screening for other complications of pregnancy such
as intra-uterine growth restriction, pre-eclampsia and stillbirth remains largely unchanged.
Randomised controlled trials of routine application of high tech screening methods to the general
population have generally failed to show improvement in outcome. We have previously reviewed
this and concluded it was due, in large part, to poor performance of screening tests. Here, we
report a study design where the primary aim is to generate clinically useful methods to screen
women to assess their risk of adverse pregnancy outcome.
Methods/design: We report the design of a prospective cohort study of unselected primiparous
women recruited at the time of their first ultrasound scan. Participation involves serial phlebotomy
and obstetric ultrasound at the dating ultrasound scan (typically 10–14 weeks), 20 weeks, 28 weeks
and 36 weeks gestation. In addition, maternal demographic details are obtained; maternal and
paternal height are measured and maternal weight is serially measured during the pregnancy;
maternal, paternal and offspring DNA are collected; and, samples of placenta and membranes are
collected at birth. Data will be analysed as a prospective cohort study, a case-cohort study, and a
nested case-control study.
Discussion: The study is expected to provide a resource for the identification of novel biomarkers
for adverse pregnancy outcome and to evaluate the performance of biomarkers and serial
ultrasonography in providing clinically useful prediction of risk.
Background
The current pattern of provision of antenatal care for low
risk women in the UK was established in 1929. Major
changes have taken place in certain aspects of care, in par-
ticular, population-based screening for fetal abnormality
[1]. These have been driven by technological develop-
ments in ultrasound, biochemical screening and molecu-
lar genetics. In contrast, the methods for screening the low
risk population for other complications of pregnancy, in
particular, intra-uterine growth restriction, pre-eclampsia
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recent years [2]. The normal approach is to assess women
for risk factors in their medical, gynaecological and obstet-
ric history at the booking visit. This is followed by serial
antenatal visits with a midwife which include measure-
ment of the symphysis-fundal height with a tape measure,
measurement of blood pressure with a sphygmomanom-
eter, and urinalysis. The recent guideline from the UK
National Institute for Clinical Excellence (NICE) on ante-
natal care addresses the assessment of "Fetal growth and
well-being in unselected women" (section 1.10). The sole
positive statement is that "Symphysis-fundal height
should be measured and recorded at each antenatal
appointment from 24 weeks" [3]. However, routine meas-
urement of symphysis-fundal height had a sensitivity of
less than 30% for detection of small for gestational age
(SGA) infants, even though the relatively broad definition
of birth weight less than the 10th percentile for gestational
age was employed [4].
One of the primary reasons for assessing fetal growth and
well-being is to prevent stillbirth, defined as death of an
infant in the perinatal period showing no signs of life.
Stillbirth accounts for 60% of all perinatal deaths and
75% of all potentially preventable losses (defined as peri-
natal death of a normally formed infant weighing 1000 g
or more) [5]. Analysis of the determinants of stillbirth
leads to the conclusion that over half are related to placen-
tal dysfunction and that many of these are associated with
impaired fetal growth [2]. Placental function can be
assessed by utero-placental Doppler flow velocimetry and
fetal growth can be assessed by ultrasonic fetal biometry.
It would seem plausible that routine application of these
tests may prevent stillbirth. However, meta-analysis of
randomised controlled trials demonstrates that use of nei-
ther methodology reduced perinatal mortality when
applied to unselected women [6,7]. Hence, in the UK and
many other countries, it is not recommended that these
tests are routinely offered to pregnant women. We have
previously reviewed the literature around stillbirth and
concluded "future work on population-based screening
for stillbirth should be preceded by high-quality, non-
interventional prospective cohort studies characterising
the screening properties of new methods of risk assess-
ment in an unselected population" [2]. Here we describe
a protocol for such a study focusing on assessing and
developing biochemical and ultrasonic indicators of pla-
centation.
Methods/design
The study design is a prospective cohort study. The cohort
is defined as primiparous women with a singleton preg-
nancy who are attending for their dating scan at the hos-
pital's ultrasound department. The initial conduct of this
study is confined to a single centre (The Rosie Hospital,
Cambridge, UK). However, it has the potential to be con-
ducted at other centres.
Recruitment and first appointment
Woman with a positive pregnancy test are told by their
midwife to contact the ultrasound department to arrange
a dating scan. When women contact the department, they
are asked if they have had any previous pregnancies
progress beyond 23 weeks. If they have not, a letter of invi-
tation and a patient information leaflet for the study are
sent. Women are approached following their dating scan.
Hence those with non-viable or multiple pregnancies are
not approached for consent. Consent is obtained by a
research midwife. Participation is explained, any ques-
tions are answered and women who agree sign the con-
sent form. The original is retained by the study, a copy is
given to the participant and a copy is placed in her clinical
case record. Routine antenatal care at the hospital involves
an ultrasound scan at 20 weeks for a detailed anatomical
scan of the fetus. For women who consent to the project,
this appointment is made on a research list where the
appointment is of one hour in duration (routine duration
is 30 minutes). Appointments (30 minute) for research
scans at 28 and 36 weeks are also made at this time and,
finally, the participant is sent for phlebotomy.
Second appointment
At the second appointment, each participant has their
detailed scan of fetal anatomy. Any abnormalities or com-
plications are dealt with by standard hospital protocols.
At the time of the scan, further information is obtained,
including maximum thickness of the placenta, the pres-
ence and dimensions of lakes, and umbilical and uterine
artery Doppler flow velocimetry. The results of the
research component of the scan are not reported. At this
visit, a brief computer assisted questionnaire is con-
ducted. The elements of this are tabulated (Table 1). Data
from the first scan are also retrieved and all information is
stored directly onto a custom built database linked to a
web-based interface and designed using Microsoft SQL
and ASP website. Maternal height and weight are also
measured and phlebotomy performed. Pre-pregnancy
weight is self reported.
The study also involves collection of a sample for DNA
from the partner and this is usually obtained at the second
appointment as the partner is often present for this scan.
An information leaflet was offered for the woman's part-
ner at the first visit. Where the partner attends, the
research sonographer explains participation, answers any
questions and obtains written consent to obtain a sample
of saliva using the Oragene© DNA collection kit. The part-
ner's height and weight are also measured.Page 2 of 8
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These visits are conducted at 28 and 36 weeks gestational
age, respectively. The formats for both are identical. A scan
is performed which includes fetal biometry, amniotic
fluid index, uterine and umbilical uterine artery Doppler
flow velocimetry, and assessment of placental maturity. In
addition, maternal weight is measured and phlebotomy is
performed. Most of the scan information is concealed.
The software on the machines which generates gestational
age estimates based on biometry is disabled preventing ad
hoc estimation of the appropriateness of measurements.
Four items of information are revealed if present, namely
(1) previously unrecognised major congenital abnormal-
ity, (2) previously unrecognised placenta praevia, (3) pro-
found oligohydramnios (amniotic fluid index less than 5)
and (4) presentation at 36 weeks.
Phlebotomy and serum/plasma storage
Samples are taken into a plain tube and an EDTA tube for
serum and plasma, respectively. They are spun in a centri-
fuge at 4°C, each sample is then separated into four aliq-
uots and placed in a -40°C freezer. Twice a day samples
are removed from the freezer and stored at -80°C. All are
split into pairs and stored in separate freezers. All freezers
are equipped with identical racking systems. The samples
are placed in 1.8 ml tubes, with 81 tubes in a box. A total
of 28 boxes are placed in a rack and the freezer contains
18 racks. Hence, each freezer has the capacity to store
40,824 tubes. The location and identity of all samples is
stored using a sample inventory software package, Pro-
Curo (Brady Laboratories), and samples are identified
using a bar coded label. Samples for maternal DNA are
stored as whole blood. The paternal salivary sample is
processed and paternal DNA is also stored at -80°C. All
freezers are connected to a secure power supply, sup-
ported by the hospital's emergency generator, which is
regularly tested. All freezers are also equipped with a liq-
uid CO2 back-up system (New Brunswick Scientific)
which will maintain samples at less than -55°C for 20
hours in the event of failure of a freezer. All freezers are
connected to a phone line and will send an automated
message to technical staff in the event of a failure or a rise
of temperature greater than -65°C. A third empty freezer
is maintained at -80°C in order to accommodate samples
in the event of failure of one of the main freezers.
Delivery
Pregnant women receiving antenatal care in the UK
National Health Service generally carry hand held notes.
Women participating in the study have their hand held
notes contained in a plastic folder with the study logo to
flag their participation. Moreover, a sticker is placed in the
delivery unit section of the notes to flag the need for pla-
cental collection and a sheet with instructions is included
in the notes. This sheet includes the number for a phone
held by the on-call technician. If a woman delivers at a
time when a technician is present in the hospital, the pla-
centa is passed to the technician as soon after delivery as
practicable. The placenta is sampled as described in the
schematic shown in Figure 1. Details of the collection pro-
tocol for the samples to be used for histological, DNA,
RNA and protein analyses are given in Table 2. If the
woman delivers at a time when there is no technician
present, the placenta is placed in a dedicated fridge and
the samples processed the following morning. The details
again are described in Table 2.
Ethics
The study was approved by the Cambridge Local Research
Ethics Committee 2. Ethics applications in the UK include
a section, "A68. What are the main ethical issues with the
research?" The issue flagged in this section was our deci-
sion to conceal most of the information retrieved in the
research scans, with the exceptions listed above. The com-
mittee raised no concern regarding this arrangement but
did request changes in the nature and presentation of the
information in the patient information leaflets.
Ascertainment of outcome
All outcomes will be ascertained by trained midwives per-
forming direct examination of the woman's clinical
record. Standardised definitions will be employed, such as
the ACOG classification of pre-eclampsia [8]. In addition,
the research database will be linked using the case record
number to the hospital's IT systems. This will allow
retrieval of routine blood investigations, other targeted
Table 1: Maternal demographic data
Characteristics
Name
Date of birth (dd/mm/yy)
Current age (yr)
Marital status (married/cohabitating/single)
Occupation (free text)
Partner's occupation (free text).
Discontinued full time education (Y/N)
Age full time education stopped (yr)
Smoking status
(never/quit pre-pregnancy/quit during pregnancy/currently smoking)
If currently smoking, number per day
Alcohol use (units per week)
Current
Pre-pregnancy
Current medical condition (free text)
Current prescription medication (free text)
Previous pregnancies ending less than 24-weeks (Y/N)
If yes 1. Gestational age (wks) 2. Spontaneous (Y/N)
Use of oral contraceptive pill in the last 3 months (Y/N)
Date of last menstrual period (dd/mm/yy)
Certain of date last menstrual period (Y/N)
Duration of menstrual cycle (/28 days)Page 3 of 8
(page number not for citation purposes)
BMC Pregnancy and Childbirth 2008, 8:51 http://www.biomedcentral.com/1471-2393/8/51ultrasonic investigations, and the Delivery Unit record.
Details will also be obtained regarding admission of the
infant to the neonatal intensive care or special care units.
Analytic approach
The study design allows three major analytic approaches,
namely, analysis as a cohort study, a case-cohort study or
a nested case-control study. All three approaches are
planned. Analysis as a cohort study will employ the infor-
mation retrieved on all participants. This includes all the
maternal demographic information, information on the
partner, the mother's height and weight serially measured
through the pregnancy, and the result of the research
ultrasound scans. Analysis as a case-cohort design will be
used to determine the associations and predictive ability
of biochemical and genetic measurements on the stored
samples. In this approach, a random sample of the cohort
(the sub-cohort) is selected as the control group at the
start of the study. Biochemical and genetic measurements
are made on the sub-cohort and on all cases. The analysis
for a given adverse event compares cases with the mem-
bers of the sub-cohort who did not experience the given
outcome. The advantages of the case-cohort study design
are that a common group of controls can be selected for
all adverse outcomes [9]. It has the advantage over simply
performing the given biochemical assay on all cohort
members of substantially reducing the costs of analysis
with minimal loss of precision.
Case-cohort studies with time-to-event outcomes require
non-standard statistical analyses but those with binary
outcomes do not [10]. Thus statistical analysis of both
cohort and case-cohort designs will be performed using
logistic regression [11]. In order to avoid over-fitting of
models, multivariate analyses will use a cross validation
approach. A model will be fitted on 90% of the given
study group and then the probability of the outcome cal-
culated for each member of the remaining 10%. This proc-
Schematic of placental collection at deliveryFigure 1
Schematic of placental collection at delivery.
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probabilities are obtained for all participants in the given
analysis. The screening performance of the models will be
assessed using this predicted probability in two ways.
First, the area under the receiver operating characteristic
(ROC) curve will be estimated, with 95% confidence
intervals as a summary of its discrimination. Different
models will be compared using the method of DeLong et
al [12]. Second, the screening performance of models will
be assessed by analysis using percentiles of predicted
probability, where women in the top 5%, 10% or 20% of
predicted probability are regarded as screen positive. The
screening performance of each of the thresholds will then
be summarized in terms of sensitivity, specificity, positive
and negative predictive values and likelihood ratios.
Finally, we also plan to conduct nested case-control stud-
ies within the cohort. This approach will be used where
very expensive or labour intensive methodologies are
planned, such as proteomic analysis of serum or gene
expression array analysis of placental RNA, and will
involve sampling of cases as well as controls. These meth-
ods are generally utilized in studies trying to understand
the biology of adverse pregnancy outcome or to identify
novel biomarkers. Nevertheless, the possibility of con-
founding is still present with these approaches. Multivari-
ate analysis is impractical using these methods, given that
small numbers are employed. Our approach is to perform
a nested case-control design with one to one matching of
cases and controls on key maternal characteristics to
address the potential for confounding. Subsequent analy-
ses will, therefore, utilise paired statistical methods.
Power calculations
Clearly power calculations cannot be performed prospec-
tively for all potential analyses in the study. Moreover, we
aim to study a series of adverse outcomes which have dif-
ferent incidence rates. A key measure we aim to determine
is the sensitivity of different models for a given screen pos-
itive rate. The precision of any estimate of sensitivity can
be quantified by the 95% confidence intervals. If we take
the example of a model with 80% sensitivity, the 95% CI
will be 74–85% for 200 cases, 71–87% for 100 cases, 66–
90% for 50 cases and 56–94% for 20 cases. Taking the
example of a condition with 3% incidence (e.g., delivery
of an infant with birth weight less than the 3rd percentile),
we would obtain 60 cases with a cohort of 2000 women
and 120 cases with 4000 women. Hence, the study is
likely to provide reasonably precise estimates of sensitiv-
ity for conditions with a 3% incidence. The incidence of
preterm birth and pre-eclampsia are both likely to be
slightly higher [13,14]. However, the incidence of some
Table 2: Placental Collection
Immediate level Collection
Completed within 10 minutes of delivery of the placenta
1. Placenta Sites at the periphery of four lobules, free of visible infarction, calcification, haematoma or damage are identified. 1–2 mm 
of tissue is removed from the maternal surface (basal plate) and discarded. A "grape size" sample of placental tissue is 
then obtained from each site and washed repeatedly in chilled phosphate buffered saline. The following samples are 
obtained from each 'grape':
i. RNA: Four 5 mg pieces placed in RNA later, (Applied Biosystems, Warrington, UK), and stored at -80°C.
ii. DNA & protein: Four 50 mg pieces, frozen in liquid nitrogen and stored at -80°C.
iii. Histology: A "pea-sized" sample is fixed in 3 ml of formalin (24 hours at 4°C) and embedded in paraffin wax.
2. Placental membranes A 2 × 2 cm portion of the membranes is obtained and fixed in formalin as above.
3. Cord blood A 10 ml anti-coagulated (EDTA/citrate) sample is obtained. Peripheral blood mononuclear cells are isolated and stored in 
liquid nitrogen.
4. Umbilical Cord The following samples are obtained
i. DNA & protein: Two 100 mg pieces of cord, frozen at -80°C.
ii. Histology: One 5 mm transverse section of cord is fixed in formalin as above.
Basic level collection
Placenta is stored in a fridge and sampled within 24 hours of delivery.
1. Placenta Four 'grape size' samples are obtained and washed as described above. From each 'grape' sample, the following are 
obtained:
i. DNA & protein: Four 50 mg pieces, frozen at -80°C.
ii. Histology: A "pea-sized" sample is fixed in 3 ml of formalin as above.
2. Placental membranes A 2 × 2 cm portion of the membranes is obtained and fixed in formalin as above.
3. Umbilical cord The following samples are obtained
i. DNA & protein: Two 100 mg pieces of cord, frozen at -80°C.
ii. Histology: One 5 mm transverse section of cord is fixed in formalin as above.Page 5 of 8
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nullipara, will be lower [15]. Hence, we have an open
ended plan for recruitment, as the study will progressively
achieve power for the less common adverse outcomes
with greater cohort size.
Initial experience with study
This study commenced at the Rosie Hospital, Cambridge
UK on the 14th of January 2008. Over the first six months,
a total of 588 eligible women were approached and 340
(57.8%) agreed to participate in the study and provided
written consent. Over this period 4 (1.2%) women have
withdrawn, two of whom have relocated. No woman has
withdrawn due to any problems with the conduct of the
study and no significant negative feedback has been given,
formally or informally.
Discussion
We describe a simple design for a prospective cohort study
of unselected primiparous women. We will compare this
study with two other large scale prospective cohort studies
in pregnancy, namely, the Southampton Women's Survey
[16] and SCOPE [17]. The Southampton Women's Survey
(SWS), funded by the MRC in the UK, was a prospective
cohort study which recruited women in their reproductive
years and then aimed to study these women during their
pregnancy. A total of 12,500 women were approached
and approximately 3000 liveborn infants are to be studied
through childhood. SCOPE is a multicentre prospective
cohort study recruiting primiparous women at around 15
weeks gestational age. It commenced in Auckland, New
Zealand, but now also has centres in Australia, the UK and
Ireland and is still actively recruiting. Each study will have
its strengths and drawbacks. We will briefly discuss the
rationale for the approach we have taken.
In our study, we have limited recruitment to primiparous
women. There were essentially four reasons for doing so.
First, primiparity is associated with increased risks of a
number of adverse outcomes of pregnancy, including pre-
term birth, pre-eclampsia, stillbirth and intrapartum cae-
sarean section [18-20]. By focusing on primiparous
women, there will be a greater proportion of the cohort
who experience adverse events. Second, one of the best
predictors of the outcome of pregnancy is the outcome of
a woman's previous pregnancy. This information is clearly
not available for primipara, hence, there is a particular
need for tests to predict risk in this population. Third, any
model derived from women of mixed parity would have
to incorporate previous pregnancy outcome for those who
were multiparous. In a cohort of mixed parity, this infor-
mation will be variably present and hence complicate the
process of modelling. Finally, we plan to run this study for
at least 4 years. It is likely that a sub-set of women will
attend the hospital for consecutive pregnancies. This
would mean that, within the cohort of pregnancies, some
would be to the same women. Non-independence of
observations is a further complicating factor for statistical
analysis.
One feature of the present study is that we aim to recruit
women early in pregnancy. We have done this as there is
considerable evidence that complications in late preg-
nancy may be determined to a large extent in the first tri-
mester (see Smith 2004 [21] for review). Women in the
SWS cohort were recruited pre-pregnancy. However, this
was a major undertaking and the ratio of women
approached to women who were followed through to
pregnancy was greater than 4:1. While there are clearly
real strengths in a study design where pre-pregnancy data
are available, this involves the expense of retrieving infor-
mation from large numbers of women who do not have a
pregnancy in the timescale of the study. Understanding
the relationship between a mother's diet prior to preg-
nancy and the subsequent health of her child was a key
issue in the SWS but is not a focus of the present study,
hence the different approach.
A important feature of the present study is that we per-
form serial scans and phlebotomy through all three tri-
mesters of pregnancy. The SWS study performed scans at
19 and 34 weeks and the SCOPE study at 20 and 24
weeks. The rationale for first trimester assessment is devel-
oped above. The basis for scans and phlebotomy at 28 and
36 weeks, in addition to the early sampling, is previous
analyses of other datasets. We have previously reported
the association between circulating concentrations of
alpha fetoprotein and human chorionic gonadotrophin
in maternal blood at 15–20 weeks gestation and the risk
of stillbirth [15]. Both measures were much better predic-
tors of stillbirths at extreme preterm gestation than losses
in later pregnancy. Similarly, high resistance patterns of
uterine artery Doppler flow velocimetry at 23 weeks gesta-
tion are strongly predictive of stillbirth at extreme preterm
gestations, but weakly associated with later losses [22].
The primary intervention to prevent stillbirth is elective
delivery and this carries serious risks to the mother and
infant if performed at extreme preterm gestations. This
provides a rationale for improving methods of detecting
babies at risk of stillbirth at later gestational ages (see
review [2]). Hence, we have included ultrasonic and bio-
chemical tests at later gestations.
A distinctive feature of the present study is that relatively
basic information is retrieved about the mother. This is in
contrast to the SWS where a 90 minute interview was con-
ducted prior to the pregnancy and food frequency ques-
tionnaires and diaries were administered both in early
and late pregnancy. It is also in contrast to the SCOPE
study. This involves a 60–90 minute interview at 15 weeksPage 6 of 8
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are addressing the factors that can only be ascertained
through questionnaires, there is less impetus to have a fur-
ther study addressing the same issues. Moreover, detailed
questionnaires addressing environmental, dietary and
social history are time consuming to administer. This
reduces the number of women who can be recruited for a
given number of personnel hours. It also may serve as a
relative obstacle to recruitment if women feel inhibited
about a prolonged and detailed interview. In order to
optimise recruitment, the present study was designed to
make involvement attractive to potential participants. The
total time involved through participation in this study is
less than two hours across all four visits. Moreover, more
than half of that time is spent having ultrasound scans
performed and women generally feel very positive about
ultrasonography in pregnancy [23]. We interpret the
greater than 50% recruitment rate and the very low drop
out rate as confirming the attractiveness and acceptability
of this study design. The attractiveness of participation is
important as it may tend to encourage women from a
wider range of social and educational backgrounds. A
design which systematically recruits very highly motivated
and educated women will result in reduced rates of
adverse events and a highly selected population may also
adversely affect a study's external validity. Finally, our
study has at its core the aim of assessing markers of pla-
centation in the prediction of pregnancy outcome. The
study design reflects our belief that combined ultrasonic
and biochemical assessment of the placenta is likely to be
a better predictor of adverse outcome than maternal die-
tary or other history.
When designing the present study, a key question was
whether information obtained through a research scan
should be used for ad hoc screening of research partici-
pants. With the very few exceptions we allowed, the posi-
tion in this study was that the research scan data should
not be so employed. However, women have all ultrasonic
investigations that are normally conducted and have any
additional scans requested by the attending obstetrician,
i.e. participating in this study does not alter in any way the
routine or targeted scanning requested by clinical staff car-
ing for those recruited. The basis for concealing the
research scan information was recommendations from
NICE in the UK. Their guideline on antenatal care, which
is intended to inform all NHS activity in the UK, explicitly
states that routine Doppler and growth studies should not
be performed on unselected women [3]. The basis for
their position is the result of meta-analyses of randomised
controlled trials of these methods which failed to show
any benefit [6,7]. We flagged this issue in our application
for ethical approval and the study received approval.
Other studies have, however, taken different views. The
SWS study revealed the results of a growth scan at 34
weeks. The SCOPE study reveals the following informa-
tion: cervical length <15 mm at 20 weeks, absent or
reversed end diastolic velocity on umbilical artery Dop-
pler at 24 weeks, and abdominal circumference <10th per-
centile at 24 weeks.
The initial target recruitment for the present study is 4000
women. We estimate that this would yield approximately
120 cases of small for gestational age infants (using the
strict definition of <3rd percentile), 150–200 preterm
births, and about 80 cases of significant pre-eclampsia
(the number of cases of pre-eclampsia will depend on the
stringency of the diagnosis). These should be adequate for
most analyses planned. However, antepartum stillbirth
unrelated to congenital abnormality affects about 0.5% of
unselected primigravid women who attend for prenatal
screening [15]. Hence, we would anticipate only approxi-
mately 20 such events. This is the basis for planning open-
ended recruitment. However, samples from small num-
bers of women experiencing rare events will still be used
to identify novel biomarkers using techniques such as
proteomics and there may be potential to validate candi-
date markers in other cohorts. We will also use non-lethal
complications of pregnancy, such as intra-uterine growth
restriction, abruption and severe pre-eclampsia, as proxies
for stillbirth. This is consistent with the view that similar
processes operate in the lethal and non-lethal manifesta-
tions of these conditions [24].
The study is designed both to provide samples to evaluate
blood tests as predictors of adverse pregnancy outcome
and to provide very well phenotyped pregnancy outcome
for basic science studies. In the former case, we will use
multivariate modelling to address potential confounding.
In the latter case, samples will be provided for basic sci-
ence studies as matched cases and controls. Many transla-
tional research studies which employ an observational
design essentially ignore the possibility of confounding.
However, women who experience pregnancy complica-
tions exhibit multiple differences when compared to the
healthy population. Moreover, medical interventions will
tend to be used selectively. Taking an example of Western
blot analysis of placental expression of a protein compar-
ing women with and without pre-eclampsia, the cases and
controls are likely to differ in relation to age, parity, obes-
ity and smoking status [13,25]. Moreover, women with
pre-eclampsia are more likely to be delivered preterm and
more likely to be delivered by planned caesarean section.
Many studies applying basic science methods to the study
of human clinical material fail to account adequately for
these systematic differences and many such analyses are
conducted in a way that would be unacceptable in clinical
epidemiological research. We will address this using a
nested case-control design with one to one matching on
key maternal characteristics. This approach reflects a keyPage 7 of 8
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aim of this study i.e. to combine excellence in science with
excellence in clinical research design and analysis.
In summary, we present a simple pragmatic design for a
prospective cohort study of unselected primigravid
women. This involves quite intensive scanning, phlebot-
omy and collection of other samples, but appears to be
acceptable to the majority of such women in our initial
experience.
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